Myungmoon Rosuvastatin

Myungmoon Rosuvastatin Dosage/Direction for Use

rosuvastatin

Manufacturer:

Myungmoon Pharm

Distributor:

Star Medical Supplies
Full Prescribing Info
Dosage/Direction for Use
General Dosing Information: The usual starting dose is 10 mg to 20 mg once daily. The usual starting dose in adult patients with homozygous familial hypercholesterolemia is 20 mg once daily.
The maximum rosuvastatin dose of 40 mg (take two 20 mg tablets) should be used only for those patients who have not achieved their LDL-C goal utilizing the 20 mg dose.
Rosuvastatin can be administered as a single dose at any time of day, with or without food. The tablet should be swallowed whole.
When initiating Rosuvastatin therapy or switching from another HMG-CoA reductase inhibitor therapy, the appropriate Rosuvastatin starting dose should first be utilized and only then titrated according to the patient's response and individualized goal of therapy.
After initiation or upon titration of Rosuvastatin, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.
Pediatric Dosing: In heterozygous familial hypercholesterolemia, the recommended dose range is 5 to 20 mg orally once daily in patients 10 to 17 years of age.
Dosing in Asian Patients: Pharmacokinetic studies have demonstrated an increase in exposure to rosuvastatin in Asian subjects when compared with Caucasians. Initiation of rosuvastatin therapy with 5 mg* once daily should be considered in Asian patients.
Use with Concomitant Therapy: Patients taking cyclosporine: The dose of Rosuvastatin should not exceed 5 mg* once daily.
Patients taking gemfibrozil: Avoid concomitant use of Rosuvastatin with gemfibrozil. If concomitant use cannot be avoided, initiate rosuvastatin at 5 mg* once daily. The dose of rosuvastatin should not exceed 10 mg once daily.
Patients taking atazanavir and ritonavir, lopinavir and ritonavir or simeprevir: Initiate rosuvastatin therapy with 5 mg* once daily. The dose of rosuvastatin should not exceed 10 mg once daily.
Dosing in Patients with Severe Renal Impairment: For patients with severe renal impairment (CLcr < 30 mL/min/1.73 m2) not on hemodialysis, dosing of rosuvastatin should be started at 5 mg* once daily and not exceed 10 mg once daily.
* 5 mg dose is to be provided by other preparation instead.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in